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The Pi3K/Akt Pathway in Tumors  
of endocrine Tissues
Helen Louise Robbins1 and Angela Hague2*
1 Department of General Surgery, University Hospital Coventry and Warwickshire, Coventry, UK, 2 School of Oral and Dental 
Sciences, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK
The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is a key driver in carcinogene-
sis. Defects in this pathway in human cancer syndromes such as Cowden’s disease 
and Multiple Endocrine Neoplasia result in tumors of endocrine tissues, highlighting its 
importance in these cancer types. This review explores the growing evidence from mul-
tiple animal and in vitro models and from analysis of human tumors for the involvement 
of this pathway in the following: thyroid carcinoma subtypes, parathyroid carcinoma, 
pituitary tumors, adrenocortical carcinoma, phaeochromocytoma, neuroblastoma, and 
gastroenteropancreatic neuroendocrine tumors. While data are not always consistent, 
immunohistochemistry performed on human tumor tissue has been used alongside 
other techniques to demonstrate Akt overactivation. We review active Akt as a potential 
prognostic marker and the PI3K pathway as a therapeutic target in endocrine neoplasia.
Keywords: thyroid tumors, parathyroid tumors, pituitary tumors, adrenocortical carcinoma, phaeochromocytoma, 
neuroblastoma, gastroenteropancreatic neuroendocrine tumors, Akt/PKB kinases
iNTRODUCTiON
The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is recognized as a key pathway in carcino-
genesis, with activating mutations in the PIK3CA gene (encoding the p110 catalytic subunit of PI3K) 
or inactivating mutation in the PTEN gene (encoding phosphatase and tensin homolog deleted on 
chromosome ten) occurring commonly in diverse human tumors (1). The PI3K/Akt pathway is 
explained in depth below; however, in brief: the actions of PI3K lead to phosphorylation (and hence 
activation) of Akt to p-Akt, an effect that is antagonized by PTEN. Akt represents a key signaling 
node: it phosphorylates a plethora of downstream cytoplasmic and nuclear targets, connecting it to a 
multitude of interrelated signaling pathways, and therefore it is responsible for modulating multiple 
processes –  including cell survival, cell cycle progression, DNA repair, protein synthesis, glucose 
metabolism, differentiation, angiogenesis, and cellular migration (2–5). The central role of PI3K/Akt 
signaling in this complex network of cellular processes makes this pathway of great importance in 
cancer cells, and indeed p-Akt is known to be overexpressed in a multitude of human cancers, and 
overexpression appears to be related to poor overall survival in some cancer types (6). The PI3K/Akt 
pathway is perhaps less well studied in tumors of endocrine tissues than in other, more common, 
malignancies. Nonetheless, there is growing evidence from both human tumors and animal models 
that this pathway may play a significant role in tumors of endocrine tissues. In this review, we seek 
to explore the evidence relating to the role of the PI3K/Akt pathway in tumors of endocrine tissues, 
with particular focus on evidence from immunohistochemical studies.
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Pi3K/Akt SiGNALiNG PATHwAY
PI3K/Akt signaling in human cancer can be driven by tyrosine 
kinase receptors, G-coupled protein receptors, or mutant RAS. 
PI3K catalyzes the production of the lipid second messenger, 
phosphatidylinositol (3,4,5) trisphosphate (PIP3) from phos-
phatidylinositol (4,5) bisphosphate (PIP2). The action of PI3K 
is antagonized by PTEN, which dephosphorylates PIP3 at the 3′ 
position, returning it to its inactive form. Akt specifically binds 
the 3′-phosphorylated inositol lipids via its plekstrin homology 
domain, hence PIP3 recruits Akt to the cell membrane. Akt–PIP3 
binding results in a conformational change that opens up the 
C-terminal kinase domain of Akt for activation by phosphoryla-
tion. The Akt family comprises three highly homologous serine-
threonine kinases: Akt1, Akt2, and Akt3. For activation, each 
isoform requires phosphorylation at equivalent threonine and 
serine residues in the Akt1/2/3 molecule: first, close to the active 
site at Thr308/309/305 in a region termed the activation loop 
mediated by phosphoinositide-dependent kinase 1 (PDK1); and 
second, in a C-terminal hydrophobic motif at Ser473/474/472 
(Figure  1). The kinase responsible for the serine phosphoryla-
tion has been debated, and kinases that can phosphorylate at this 
site include integrin-linked kinase (ILK), protein kinase Cβ2, 
DNA-dependent protein kinase (DNA-PK), and ataxia telangiec-
tasia mutated (ATM) (7). Akt can also autophosphorylate at this 
residue if the plekstrin homology domain is exposed (allowing 
recruitment to the plasma membrane) and the threonine residue 
(Thr308 in Akt1) is phosphorylated (8). However, the mTORC2 
complex is now believed to be the main kinase responsible for 
phosphorylation at the Ser473/474/472 position.
Akt is phosphorylated at multiple sites by PI3K-independent 
mechanisms, for example tyrosine kinases such as Ack1/TNK2, 
Src, and protein tyrosine kinase 6 (PTK6) and serine/threonine 
kinases such as IKKϵ, TANK-binding kinase 1 (TBK1), Mre1/
ATM, or DNA-PKcs. These modifications may alter Akt confor-
mation and contribute to cancer development or tumor resistance 
to inhibition of PI3K [reviewed in Ref. (12)]. Recently, cyclin A/
cyclin-dependent kinase-2 complexes have been reported to 
phosphorylate Akt1 at S477 and T479, stabilizing the C-terminal 
tail and promoting its kinase activity and ability to protect against 
apoptosis. Hence, Akt activity may be intimately linked with the 
cell cycle. S477/T479 phosphorylation may also prime Akt1 for 
mTORC2-mediated phosphorylation at S473 (13).
Akt is negatively regulated by the Pleckstrin homology domain 
leucine-rich repeat protein phosphatases 1 and 2 (PHLPP1/2), 
which selectively dephosphorylate Akt at the Akt1 Ser(473) site, 
while protein phosphatase PP2A dephosphorylates Akt at the 
Thr(308) site (8). PHLPP1 and PHLPP2 show relative specificity 
for different Akt isoforms. For example, in pancreatic adenocarci-
noma cells, PHLPP1 selectively dephosphorylated Akt2, whereas 
PHLPP2 selectively dephosphorylated Akt1 (14).
In addition to its activation at the plasma membrane, Akt can 
be activated by nuclear pools of PI3K, and PDK1 and DNA-PK 
(15). In this regard, it is unsurprising that Akt is considered a 
signaling hub for tumor cells and the PI3K/Akt/mTOR pathway 
in particular has been the interest of targeted drug development 
(16).
Mammalian target of rapamycin (mTOR) is a serine/
threonine kinase that forms two complexes, mTOR complex 1 
(mTORC1) and mTOR complex 2 (mTORC2), implicated in 
carcinogenesis. Akt removes inhibition of mTORC1 (consisting 
of mTOR, mLST8, Raptor, PRAS40) by targeting the negative 
regulators tuberous sclerosis protein 2 (TSC2) and proline-rich 
Akt substrate of 40 kDa (PRAS40) by direct phosphorylation (4) 
and by indirect inhibition of TSC2 through GSK3β phosphoryla-
tion [reviewed in Ref. (17)]. mTORC1 phosphorylates ribosomal 
S6 kinase (70 kDa S6K1 or p70RSK), and eIF4E-binding proteins 
(4E-BPs) to enhance protein synthesis. mTORC2 (consisting of 
mTOR, mLST8, Rictor, Sin1) can act as the PDK2 for Akt and 
phosphorylate it at serine 473, but is not thought to function 
downstream of Akt (17).
There are a number of negative feedback mechanisms that 
control signaling through the PI3K/Akt/mTOR pathway that 
need to be considered when designing drug targeting strategies 
for human cancer. mTOR inhibition induces activation of Akt 
signaling pathways, through elimination of negative feedback 
loops. Ultimately, this may lead to growth escape and drug 
resistance, limiting the effectiveness of mTOR inhibition, and 
therefore combination treatments could be promising (18–20). 
The feedback loops that normally quench Akt signaling have been 
reviewed by Rozengurt et al. (21). mTOR inhibition prevents neg-
ative feedback mechanisms; in one of these S6K1 phosphorylates 
IRS-1 (insulin receptor substrate-1) causing it to dissociate from 
tyrosine kinase receptors; in another mTORC1 phosphorylates 
GRB10 which suppresses insulin and IGF receptor kinase activity 
and facilitates their degradation; and in a third mTORC2 assem-
bly is prevented by phosphorylation of Sin1, mediated by S6K or 
Akt depending on the cell type. Whereas mTORC1 is sensitive 
to inhibition by rapamycin (sirolomus), mTORC2 is generally 
insensitive meaning Akt phosphorylation at Ser473 is enhanced 
with treatment because of inhibition of the latter feedback loop, 
although in some cell types long-term treatment with rapamycin 
can block mTORC2 assembly [reviewed in Ref. (22)]. Active 
site mTOR inhibitors function against mTORC1 and mTORC2, 
reducing phosphorylation of Akt at Ser473 but enhancing that 
at Thr308. Dual active site inhibitors of PI3K and mTOR are 
therefore useful to damp down the activation of the pathway; 
however, these elicit compensatory signaling through the MEK/
ERK pathway. Hence researchers are currently investigating the 
potential for combining inhibition of tyrosine kinase receptors 
with mTOR targeting (21).
iMMUNOHiSTOCHeMiCAL ANALYSiS OF 
Akt ACTivATiON
Immunohistochemistry for p-Akt has been used to assess the 
relevance and implications of the activation of the PI3K/Akt 
pathway in human cancers. Activation of Akt may be assessed 
through use of phospho-specific antibodies, raised against either 
phospho-Ser473-Akt or phospho-Thr308-Akt. These antibodies 
recognize all three phosphorylated Akt isoforms (23). Caution 
needs to be taken in assessing phospho-specific protein detection 
by immunohistochemistry, since delayed fixation can reduce the 
FiGURe 1 | The Pi3K/Akt pathway. Akt is recruited to the plasma membrane by phosphatidylinositol (3,4,5) trisphosphate (PIP3) produced from 
phosphatidylinositol (4, 5) bisphosphate (PIP2) by phosphatidylinositol 3-kinase (PI3K). PTEN is a phosphatase that promotes the reverse reaction. For activation, 
Akt is phosphorylated on Thr(308) by phosphoinositide-dependent kinase 1 (PDK1) and on Ser(473) primarily by the mTORC2 complex serving as PDK2. Upon full 
activation, Akt leaves the membrane and can adopt a nuclear or cytosolic localization. There are over 70 known molecular targets of the Akt kinase and the three 
targets believed to be the most important in carcinogenesis are shown. By phosphorylation of TSC2, Akt relieves its repressive effects on Rheb, resulting in 
downstream activation of the mTORC1 complex and enhanced RNA translation. GSK3β is a tumor suppressor, which targets a number of proliferation and survival 
regulators, including β-catenin and Mcl-1, and elevates activity of TSC2 [reviewed in Ref. (9)]. The family of forkhead transcription factors, FoxO, upregulates genes 
controlling cell cycle arrest and apoptosis and is inhibited by Akt. Whereas GSK3β and TSC2 can be phosphorylated by p-Akt(Thr308) in cells, phosphorylation at 
Ser(473) is critical to inactivate FoxO proteins [reviewed in Ref. (8)]. When these are phosphorylated they become transcriptionally inactive and subject to nuclear 
export. FoxO3A exhibits reduced nuclear expression in the majority of thyroid cancers in association with high levels of p-Akt(Ser473), and relevant FoxO3A 
downstream target genes have been identified in follicular rat thyroid cells (10) and subsequently in benign (FRTL-5) and malignant human thyrocytes (FTC-133) (11), 
as the CDKN1B gene encoding cyclin-dependent kinase inhibitor, p27KIP1, and BCL2L11, encoding Bim, a pro-apoptotic member of the Bcl-2 family of proteins.
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FiGURe 2 | Percentage of tumors with mutations affecting MAPK or 
Pi3K/Akt signaling pathways in thyroid cancer histotypes of follicular 
cell origin. Data obtained from the COSMIC, 2014 (32) database 
considering the top 20 mutations (accessed 16/12/2015). Numbers of 
samples: papillary, 19239; follicular, 253; anaplastic, 564; mixed papillary and 
follicular, 69.
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efficiency of staining and larger tumors can sometimes appear 
negative in the center of the fixed sample (24, 25). With this in 
mind, p-Akt has been used to determine a snapshot of Akt signal-
ing in tumor specimens, with a view to its utility as a prognostic 
or predictive marker.
Ocana et al. (6) conducted a meta-analysis of reports in the 
literature of PI3K/Akt activation in solid tumors and overall 
survival. Eligibility criteria were the availability of survival data 
for at least 5 years in relation to three types of pathway aberra-
tions (i) mutations in the PI3K gene, (ii) lack of PTEN expression 
by immunohistochemistry or western-blot, or (iii) evaluation 
of downstream components of the PI3K/Akt pathway such as 
Akt itself or downstream targets including phospho-S6, mTOR, 
phospho-mTOR, or phospho-4EBP1 by immunohistochemistry. 
Overall, they found an association between defects in the PI3K/
Akt/mTOR pathway and poor 5-year survival. While the number 
of tumor types for which this information was available was small, 
the association was more marked in gastrointestinal tumors and 
gynecologic cancers than others. A recent meta-analysis of breast 
cancer patients showed significant association between p-Akt 
overexpression and worse overall survival (6,349 patients from 20 
studies) and worse disease-free survival (8,683 patients from 24 
studies) (26). There was no significant difference between patient 
groups according to stage of cancer, estrogen receptor status, 
progesterone receptor status, and HER2 status. Between-study 
heterogeneity was attributed by the authors at least in part to dif-
ferent scoring methods for p-Akt status and definitions of p-Akt 
overexpression. They called for a standardized assay methodol-
ogy, which would help to determine whether Akt inhibition is 
likely to be an effective targeted cancer treatment.
The number and size of studies investigating the activation of 
the PI3K/Akt pathway in cancers of endocrine tissues are small 
and do not include 5-year overall survival data, but consideration 
of what is known on this subject will help to define the relevance 
of defects in this pathway to carcinogenesis and future approaches 
to therapy.
THYROiD CANCeR
As the most common cancer of endocrine tissues, thyroid carci-
nomas are the most well studied. Immunohistochemical studies 
are corroborated by genetic analysis and animal models to pro-
vide strong evidence for an important function of the PI3K/Akt 
pathway in thyroid carcinogenesis. Thyroid carcinoma includes 
well-differentiated thyroid cancers of the papillary, follicular, 
and Hurthle cell types (of which papillary tumors are the most 
common), and undifferentiated or anaplastic thyroid cancer. 
Although uncommon, anaplastic thyroid cancer is aggressive 
with a high mortality rate and is believed to arise by anaplastic 
transformation from pre-existing follicular and papillary tumors 
through distinct genetic pathways (27). These cancers are derived 
from the follicular cells, whereas medullary carcinoma is derived 
from the C cells of the thyroid. A role for the PI3K/Akt pathway in 
thyroid carcinogenesis was first suggested by propensity of patients 
with Cowden’s syndrome, an autosomal dominant multi-organ 
hamartoma syndrome, to develop thyroid tumors. Germline 
mutations in PTEN underlie 80% of Cowden’s syndrome cases. 
Other cases result from germline promoter hypermethylation 
resulting in transcriptional down-regulation of KILLIN, a pro-
apoptotic gene sharing PTEN promoter sequences, or germline 
mutations and variants in the succinate dehydrogenase genes 
(SDHx), which result in elevated Akt and MAPK signaling (28), 
or mutation in either PIK3CA or AKT1 (29).
The Cancer Genome Atlas Network reported that 61.7% 
of papillary thyroid cancer tumors had BRAF mutations, with 
a predominance of V600E substitutions (30) and 12.9% had 
mutations in RAS genes. “BRAFV600E-like tumors” had gene 
signatures distinctly different to “RAS-like tumors.” The former 
signal through MAPK to strongly activate ERK, whereas the 
latter signal through MAPK preferentially via c-RAF and addi-
tionally activate the PI3K pathway. The Catalogue of Somatic 
Mutations in Cancer (COSMIC, 2014, 31, 32) indicates that the 
incidence of BRAF mutation is strikingly higher in papillary than 
follicular or anaplastic cancers and that mutations in the RAS 
genes are more common in papillary thyroid cancers. Mutations 
in the PI3K/Akt pathway are a feature of follicular and anaplastic 
tumors and are less frequent in papillary tumors (Figure  2). 
Ricarte-Filho et  al. (33) found BRAF mutation to be more 
common in radioactive iodine-resistant recurrent or metastatic 
thyroid carcinomas compared with poorly differentiated primary 
tumors, which more frequently harbored NRAS mutations. They 
reported that AKT1 mutations were detected only in metastases 
and that different metastases from the same individual could 
exhibit PIK3CA mutations or AKT1 mutations, leading them 
to suggest that defects in the PI3K/Akt pathway occur during 
tumor progression, and that use of primary cancer material to 
stratify patients for specific therapies may not be the most effec-
tive strategy. However, mutation tells only part of the story, and 
changes in gene copy number, expression and protein stability 
may contribute to over-activation of the PI3K/Akt pathway.
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ANiMAL MODeLS OF THYROiD CANCeR
Rodent models have provided evidence for elevated PI3K/Akt 
signaling in thyroid carcinogenesis. PTEN+/− mice serve as a 
model of Cowden’s disease and develop diverse types of tumor 
including prostate, endometrium, thyroid, adrenal medulla, and 
small intestine tumors. Chen et  al. (34) crossed PTEN+/− mice 
with Akt1−/− mice to determine whether this would attenuate 
the propensity for tumor development. While the most marked 
reduction in tumor incidence was observed in the prostate, 
endometrium, and small intestine, Akt deficiency significantly 
reduced the incidence of thyroid tumors and high grade tumors of 
the adrenal medulla. Mice in which thyroid follicular cell specific 
PTEN deletion is achieved by thyroid peroxidase Cre-mediated 
recombination exhibit a marked increase in follicular cell 
p-Akt(Ser473) immunoreactivity and proliferation and develop 
follicular adenomas (35). The Akt target FoxO1, the mTOR target 
p70S6K1, and downstream S6 were highly phosphorylated in the 
mutant thyroids. Although PTEN+/−PHLPP1−/− mice are available 
(36), the role of PHLPP in thyroid and adrenal medulla carcino-
genesis has yet to be explored. Neither have any studies addressed 
PHLPP expression in human thyroid cancer.
The TRPV mouse model makes use of the fact that the thyroid 
hormone receptor (TR) is a tumor suppressor for thyroid cancer 
(37). The PV mutation results in loss of thyroid hormone binding 
to the receptor and transcriptional activity and a knock-in mouse 
carrying two mutant TR alleles (TRβPV/PV) exhibited spontaneous 
follicular thyroid carcinomas, while TRβPV/+ heterozygous mice 
did not. Kim et al. (38) examined subcellular localization of Akt 
in the thyroid of such mice by both immunohistochemistry and 
confocal microscopy. All three Akt isoforms were overexpressed 
in the thyroid cancers of older TRβPV/PV mice compared to age-
matched wild-type controls. In primary tumors, Akt1 was chiefly 
in the nucleus, Akt2 and Akt3 were primarily cytosolic and 
p-Akt(Ser473) was both nuclear and cytoplasmic. In metastases, 
all three Akt isoforms and p-Akt(Ser473) were primarily nuclear. 
Functional studies of the PI3K/Akt pathway were carried out by 
treating primary TRβPV/PV thyroid cells with the PI3K inhibitor 
LY294002 or transducing them with dominant negative Akt, both 
of which reduced cell motility in transwell assays.
Pringle et al. (39) generated mice with thyroid-specific knock-
out of both PRKAR1A and PTEN genes. PRKAR1A encodes the 
type 1A regulatory subunit of protein kinase A (PKA); when this 
gene is inactivated, PKA activity is enhanced. Single PRKAR1A 
knockout (R1a-TpoKO) mice develop thyroid cancer, but do not 
exhibit metastases. By contrast, the PRKAR1A-PTEN double 
knockout (DRP-TpoKO mice) developed aggressive follicular 
carcinomas, which frequently metastasized to the lungs. PTEN 
single knockout thyroids (pten-TpoKO) only developed benign 
follicular hyperplasia, but there was diffuse nuclear and cyto-
plasmic p-Akt staining and increases in phosphorylated mTOR 
and p70S6K. p-Akt staining in DRP-TpoKO tumors exhibited 
membranous localization. Pringle et  al. (39) hypothesized that 
PKA may redirect Akt to a membranous localization and that, 
independently, PKA may contribute to the activation of mTOR. 
This is consistent with their immunohistochemical analysis 
suggesting that a higher proportion of follicular carcinomas 
overexpress p-p70S6K than p-Akt, although it would be useful to 
expand the number of follicular carcinomas analyzed.
While most studies of p-Akt have utilized genetic mouse 
models, a rat two-stage chemically induced thyroid cancer 
model has also been informative. The thyroid carcinogen 
N-bis(2-hydroxypropyl)nitrosamine followed by promotion 
using sulfadimethoxine for 10 and 15  weeks was sufficient to 
induce focal follicular cell hyperplasia, follicular cell adenomas, 
and carcinomas (40). This study compared staining using Akt1, 
Akt2, p-Akt(Ser473), and p-Akt(Thr308) antibodies as well as 
antibodies to PTEN, p-PTEN, GSK3β, and p-GSK3β(Ser9). 
Staining intensity and incidence for Akt1 and Akt2 were 
increased in carcinomas compared to focal follicular cell 
hyperplasia, as was p-Akt(Ser473) and p-Akt(Thr308). PTEN 
and GSK3β are both inactivated by phosphorylation. Although 
PTEN staining was higher, so was staining for inactive p-PTEN, 
suggesting that inactive p-PTEN accumulation may underlie 
Akt activation in these tumors. The elevation of p-GSK3β(Ser9) 
staining intensity observed in the tumors was further indication 
of increased Akt activation.
eviDeNCe FOR Akt ACTivATiON iN 
HUMAN THYROiD CARCiNOMA
There is growing evidence from examination of Akt phospho-
rylation that Akt signaling has a role in sporadic thyroid cancers 
[reviewed in Ref. (40, 41)]. Ringel et al. (42) examined levels of 
p-Akt(Ser473) and Akt1, Akt2 and Akt3 in 8 follicular thyroid 
cancers, 9 papillary thyroid cancers, and 11 normal thyroid 
samples by western blotting and observed increased Akt1, 
Akt2 and p-Akt(Ser473) in follicular but not papillary cancers. 
By contrast, also using western blotting, Miyakawa et  al. (43) 
compared seven matched pairs of papillary thyroid cancer and 
adjacent normal tissue and found total Akt levels unchanged, but 
there was significantly higher p-Akt in tumor tissue compared to 
surrounding tissues (five of seven pairs), with elevated levels of 
activated downstream targets p-Bad and p-p70S6K. Mandal et al. 
(44) also found elevated levels of p-Akt(Ser473) in six out of eight 
papillary thyroid cancers compared to adjacent normal tissue, 
whereas total Akt levels were similar. Krzeslak et  al. (45) used 
an ELISA method, and found enhanced levels of cytoplasmic 
Akt1 in 23 thyroid carcinomas compared with 16 non-neoplastic 
lesions (nodular goiters). The majority of Akt1 was cytosolic in 
differentiated cancers whereas two of three anaplastic cancers 
showed lower cytosolic and higher nuclear Akt1 expression. 
However, when Akt1 immunoprecipitates were examined by 
immunoblotting, the ratio of p-Akt(Ser473) to total Akt1 was 
lower in cancers compared to normal tissues (although only a 
subset of the tumors were shown to be analyzed in this way and 
it is unclear if the anaplastic cancers with high nuclear Akt1 were 
included). On this basis, the authors proposed that either Akt2 
or Akt3 might be activated in thyroid cancers rather than Akt1.
Levels of PTEN regulate the extent to which Akt is phospho-
rylated. Exogenous overexpression of PTEN in ARO or FB-1 cells 
caused decreased p-Akt(Ser473) and increased p27KIP1 expression 
leading to cell cycle arrest with no evidence of apoptosis. In a 
TABLe 1 | Results of immunohistochemical staining studies for p-Akt(Ser473) in thyroid tumors.
Antibody Specimens Key results Author 
(reference)
Tumours arising from follicular cells
p-Akt(Ser473) CST 1:50 115 PTC on TMA (Korean cohort) 10 cases showed clear nuclear staining (cytoplasmic p-Akt staining observed 
in approximately half of the samples was considered to be non-specific)
Shin et al. (51)
p-Akt(Ser473) CST 1:100 66 normal thyroid
20 FA
10 FTC
26 PTC
10 follicular variant papillary (samples 
from Ukraine and Tokyo)
p-Akt staining rare in normal thyroid samples (4/66). Nuclear p-Akt in 8/20 FA 
in areas near vessels or in atypical cells and in FTC regions of capsular and 
vascular invasion (10/10)
Vasko et al. (48)
Both nuclear and cytoplasmic p-Akt in invasive regions and lymph node 
metastases of all PTC compared with adjacent normal tissue. Only 2/8 FVPC 
p-Akt positive
p-Akt(Ser473) 38 ATC (samples from Spain and  
Italy)
p-Akt detected in high proportion of anaplastic thyroid cancers, associated 
with proliferation. Only focal staining in normal tissue
Garcia-Rostan 
et al. (49)
p-Akt(Ser473) CST 1:250 100 thyroid tumors (10 FA, 62 PTC, 
23 FTC, 5 ATC) (Italy cohort)
Expression more common in carcinomas than benign tumors. Associated  
with cytoplasmic p27 KIP1 localization, but not with tumor differentiation
Motti et al. (52)
p-Akt(Ser473) 8 PTC, 8 HT, 8 HT + PTC, 34 normal 
(samples from USA)
Hashimoto’s thyroditis and cancer showed increased p-Akt. p-Akt higher in 
cancer with Hashimoto’s thyroiditis than cancer alone
Larson et al. (50)
p-Akt(Ser473) CST 536 PTC on TMA (Saudi Arabian 
cohort)
Paper reports on c-Met. p-Akt staining referred to as data not shown.  
55% p-Akt positive; significantly associated with c-Met overexpression
Siraj et al. (54)
p-Akt(Ser473) CST 27 ATC 16 (59.3%) p-Akt positive Liu et al. (55)
25 FTC (samples from USA) 16 (64%) p-Akt positive
p-Akt(Ser473) CST 26 ATC (samples from USA) p-Akt detected in 22/26 anaplastic thyroid carcinomas. All had cytoplasmic 
staining and 17 of them had nuclear. Associated differentiated thyroid 
carcinoma, where present, exhibited only cytoplasmic p-Akt
Santarpia  
et al. (56)
p-Akt(Ser473) CST 463 PTC on TMA (Saudi Arabian 
cohort)
255/463 overexpressed p-Akt Uddin et al. (57)
Fatty acid synthase expression significantly associated with p-Akt expression
p-Akt Rabbit mAb  
CST 1:500
196 benign and malignant tumors  
(65 FA, 68 FTC, 63 PTC)
Strong p-Akt staining intensity in 65% of FTC and in 70% of PTC. Very faint 
and present in <13% of FA and <5% of normal thyroid. Positive correlation 
with cytoplasmic FoxO3A staining.
Karger et al. (10)
10 normal (samples from Germany)
p-Akt(Ser473) CST 2 ATC versus 23 normal thyroid  
(USA samples)
Stronger cytoplasmic p-Akt in tumors compared with nuclear and cytoplasmic 
staining in normal. Greatly increased nuclear mTOR in the tumors
Liu and  
Brown (58)
p-Akt(Ser473) CST 1:50 83 PTC (samples from Greece) Trend for increased expression in tumors with aggressive features. High levels 
in tumors with PIK3CA and PTEN mutations
Sozopoulos  
et al. (59)
p-Akt(Ser473) CST 1:50 35 PTC; 16 with associated lymph 
node metastasis compared with  
19 without (samples from Spain)
No difference in p-Akt staining between tumors with associated metastasis 
and those without
Zafón et al.a (60)
p-Akt(Ser473) CST 25 PTC Staining greater at the invasive front and cells infiltrating vasculature. 
Associated with connexin 43.
Jensen et al. (53)
10 FTC (samples from Finland)
p-Akt(Ser473) CST 30 PTC (15 classical and 15 
histological variants) (USA samples)
Low to moderate staining for p-Akt in all cancers. Enhanced nuclear  
p-mTOR in aggressive variants
Liu and  
Brown (61)
(Continued)
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panel of 13 human thyroid carcinomas, there appeared to be an 
inverse correlation between PTEN and p-Akt(Ser437) levels as 
measured by western blotting, although with low numbers this 
was not quantified and analyzed statistically (46). Gimm et  al. 
(47) stained 139 benign and malignant non-medullary thyroid 
tumors for PTEN and measured loss of heterozygosity in 92 
tumors informative at the PTEN locus. This generated a picture 
of progressive loss of staining and increased frequency of PTEN 
allelic loss with progression to malignancy and an aggressive 
phenotype.
Results of p-Akt immunohistochemistry studies of human 
thyroid cancers are summarized in Table 1. Papillary, follicular, 
and anaplastic thyroid cancers exhibit increased p-Akt(Ser473) 
expression compared with normal tissue (48–50). One study 
reported clear p-Akt(Ser473) staining in only a minority or 
thyroid cancers, but this discrepant result appears to be due to 
cytoplasmic staining being judged as non-specific in this report 
(51). Detection of p-Akt(Ser473) in benign follicular adenomas is 
uncommon, but it is detectable in atypical cells of atypical adeno-
mas, and frequent in follicular thyroid cancer – suggesting that 
Akt activation may play a role in the malignant phenotype (48, 
52). This is further supported by the finding that p-Akt(Ser473) 
expression is greater at the invasive front of cancers, and also 
increased in cells invading the vasculature (48, 53).
Liu et al. (55) observed p-Akt(Ser473) immunoreactivity in 
16/25 follicular thyroid cancers, and found genetic alterations 
in the PI3K/Akt pathway to account for all of these, includ-
ing copy gains of PIK3CA, PIK3CB, and AKT2. In anaplastic 
Antibody Specimens Key results Author 
(reference)
p-Akt(Ser473) Rabbit 
polyclonal CST
536 PTC on TMA (Saudi Arabian 
cohort)
Of 446 informative TMA results, 242 (54.3%) were classified as high  
p-Akt and 204 (45.7%) as low (Table 2 in Supplementary Material of the 
paper); highly significant correlation with mTORC2 activity as measured using 
mTOR(Ser2482) antibody staining (P < 0.0006)
Ahmed et al. (62)
p-Akt(Ser473) 
Novacastra NCL-L-Akt-
Phos 1:40
12 ATC (samples from Serbia) High p-Akt in 5/12 (41.6%), high p-ERK in 7/12 (58.3%), low level PTEN  
in 6/12
Milosevic et al. 
(63)
Significant negative correlation between p-Akt staining and NRAS gene 
mutations/p-ERK staining
p-Akt(Ser473) CST 42 tumor samples (5 FTC,10 
conventional PTC, 8 aggressive PTC, 
3 poorly differentiated classified as 
PTC; 16 MTC) (samples from Greece)
Strong positive association between p-Akt(Ser473) and Sin1 protein 
expression (all 42 tumors combined)
Moraitis et al. (64)
p-Akt(Ser473) CST 
Rabbit polyclonal (9271)
10 normal thyroid Overexpression in 57% of PTC, and 30% of FTC. FVTC did not overexpress 
p-Akt
Pringle et al. (39)
30 PTC
5 FVTC
10 FTC (samples from Ukraine)
p-Akt(Ser473) CST 1022 PTC on TMA (Saudi Arabian 
cohort)
Paper focused on XIAP. Highly significant association between XIAP  
staining and p-Akt staining
Hussain et al. (65)
Medullary thyroid cancers (tumours arising from C cells)
p-Akt(Ser473) Rabbit 
polyclonal CST (736E11) 
1:1000
TMA 38/49 showed positive staining Rapa et al. (66)
49 MTC (samples from Italy) Associated with p-mTOR and p-p70S6K, but not with clinical features, 
pathological features, prognosis, or RET mutation status
p-Akt(Ser473) Rabbit 
polyclonal CST (736E11) 
1:50
TMA Expressed in all tumors, but mostly weak. No significant association  
with patient outcome
Erovic et al. (67)
23 MTC
Normal thyroid control (USA cohort)
p-Akt (Ser473) CST1:50 
and p-Akt (Thr308) 
CST1:25
TMA
18 hereditary MTC
35 sporadic MTC
37 C cell-free thyroid tissue
Tissue sections
20 MTC (USA cohort)
C cell-free thyroid tissue negative for both p-Akt(Ser473) and p-Akt(308)
12/21 (43%) primary MTCs positive for p-Akt(Thr308)
1/1 LNM positive for p-Akt(Thr308)
36/46 (78%) primary MTCs positive for p-Akt(Ser473)
15/19 (79%) LNM positive for p-Akt(Ser473) (see Table S2 in  
Supplementary Material of the paper)
Tamburrino et al. 
(68)
aArticle in Spanish.
CST, Cell Signaling Technology; mAb, monoclonal antibody; FA, follicular adenoma; PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; ATC, anaplastic thyroid 
carcinoma; MTC, medullary thyroid carcinoma; HT, Hashimoto’s thyroditis, FVPC, follicular variant papillary carcinoma; TMA, tissue microarray; LNM, lymph node metastasis.
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cancers 16/27 showed p-Akt(Ser473) immunoreactivity. The vast 
majority (95.8%) of anaplastic thyroid cancers had genetic 
alterations resulting in activation of both the PI3K and MAPK 
pathways, including frequent co-existence of receptor tyrosine 
kinase copy number gain and gene mutation, as well as PIK3CA, 
PIK3CB, and PDK1 copy number gains, PTEN mutation and 
BRAF mutation. Furthermore, RAS activation can result in 
activation of the PI3K/Akt pathway in thyroid carcinoma (69). 
However, a recent study of 12 anaplastic carcinomas reported 
that p-Akt(Ser473) staining inversely correlated with p-ERK 
staining and NRAS gene mutations, perhaps suggesting that only 
one of these two signaling pathways might drive progression to 
anaplastic tumors (63).
Overexpression of upstream receptors can elevate levels of 
p-Akt in thyroid cancers. Liu et  al. (55) found that EGFR and 
VEGF1 copy number gain was particularly common in both 
follicular and anaplastic thyroid cancer. Rearranged during 
transfection (RET ) is a tyrosine kinase receptor proto-oncogene, 
point mutation of which underlies Multiple Endocrine Neoplasia 
Types 2A and 2B (MEN2A/MEN2B) and familial medullary 
thyroid cancer. Some papillary thyroid carcinomas, including 
those arising after ionizing radiation exposure, develop through 
translocations resulting in fusion of RET with 1 of 13 other 
genes (RET/PTC rearrangements) (70) producing a protein with 
constitutively active tyrosine kinase signaling. There is evidence 
to show that a MEN2A-type mutant RET results in constitutive 
activation of the PI3K/Akt pathway (71), and papillary cancers 
with RET overexpression due to gene rearrangements demon-
strated the greatest p-Akt levels and throughout the tumors (48). 
c-Met, the hepatocyte growth factor receptor, was associated with 
p-Akt expression in papillary thyroid carcinomas in a Middle 
Eastern population in which PIK3CA mutation was rare (54). 
The tyrosine kinase receptor EphA2 is overexpressed in benign 
and malignant thyroid tumors and has been shown to contribute 
to p-Akt activation (72).
Downstream targets have been associated with high levels of 
p-Akt(Ser473). The majority of thyroid cancers exhibit reduced 
nuclear FoxO3A (10), and FoxO3A downstream target genes 
CDKN1B encoding cyclin-dependent kinase inhibitor p27KIP1, 
and BCL2L11 encoding Bim, a pro-apoptotic member of the 
Bcl-2 family of proteins, have been identified as functionally 
relevant in follicular rat thyroid cells (10) (Figure 1). Inhibition 
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of PI3K/Akt signaling by LY294002 resulted in reduced 
FoxO3A phosphorylation and its accumulation in the nucleus, 
and increased p27KIP1 and Bim mRNA in vitro. Vasco et al. (48) 
reported that invasive regions of papillary and thyroid cancer 
were characterized by both nuclear p-Akt and nuclear exclu-
sion of p27KIP1 and used a human papillary thyroid cancer cell 
line (NPA) to link p-Akt and cytoplasmic exclusion of p27KIP1 
with invasive capacity in a transwell assay. In addition, Bad 
and XIAP have been noted as relevant Akt targets in papillary 
thyroid carcinoma cells (62, 65), contributing to protection 
from apoptosis.
Enhanced nuclear p-mTOR suggests the activation of the 
PI3K/Akt/mTOR pathway in aggressive variants of papillary 
thyroid carcinomas (61). The Al-Kuraya group have performed 
tissue microarray immunohistochemistry for p-Akt(Ser473) and 
related proteins on a large series of papillary thyroid carcinomas 
of Middle Eastern origin, enabling correlative expression studies 
to be performed (albeit with some loss of informative spots on 
different staining runs). In a recent study, p-mTOR(Ser2448) was 
used as a marker of mTORC1 activity and was detected in 81% of 
tumors, while p-mTOR(Ser2481), a marker for mTORC2 activity 
was observed in 39%. There was a strong positive correlation with 
p-Akt(Ser473) and p-mTOR(Ser2481) staining, as well as activa-
tion of further Akt and mTORC1 target proteins. As evidence 
for the concept that both mTOR complexes are actively involved 
in regulating the survival of papillary thyroid carcinoma cells, 
Torin 2, a dual mTORC1/2 inhibitor, induced apoptosis in two 
papillary carcinoma cell lines, BCPAP and TPC, in association 
with reduced activity of Akt and downstream targets of p-Akt and 
mTOR complexes (62).
Strong positive association has been observed between 
staining for p-Akt(Ser473) and Sin1 protein, a component of 
the mTORC2 complex, in a series of 42 tumor samples, which 
included 16 medullary thyroid cancers (see below). This was a 
characteristic of aggressive papillary and medullary carcinomas 
and therefore further staining of larger cohorts for p-Akt in 
conjunction with Sin1 is worthwhile, since normal thyroid tis-
sues showed no expression or <10% weakly Sin1 positive cells 
(64). In these cells, S6K appeared to be the relevant Sin1 kinase. 
In a series of 58 ovarian cancer specimens, p-Akt(Ser473) and 
p-Sin1(Thr86) staining were, if anything, negatively correlated, 
but this did not reach statistical significance. The generation of 
the phospho-specific Sin-1 antibodies, along with the discovery 
that mutation of the Sin1 phosphorylation sites occurs naturally 
in ovarian and skin cancers and abrogates the negative control on 
Akt activity (73), could be helpful in determining the mechanisms 
for the positive association between p-Akt(Ser473) and Sin1 in 
thyroid cancers.
Whether p-Akt(Ser473) expression is associated with actual 
patient prognosis has yet to be measured in thyroid cancer, and 
only inferences can be made from the literature. p-Akt(Ser473) 
was not associated with likely prognosis of papillary carcinoma 
(59). In a more recent study, the Al-Kuraya group stained for the 
anti-apoptotic protein XIAP on tissue microarray. Of 989 tumors 
producing informative staining for p-Akt(Ser473), 57.1% exhib-
ited staining classed as high, and there was a highly significant 
positive association with staining for XIAP (65). XIAP staining 
was associated with poor disease free survival, but the study did 
not report on p-Akt directly in relation to prognosis.
Patterns of p-Akt staining have been reported to vary between 
follicular and papillary carcinomas, but more prominent nuclear 
p-Akt(Ser473) was reported in regions of invasion in both types 
(48). Similarly, while differentiated thyroid cancers demonstrate 
cytoplasmic staining, contiguous anaplastic thyroid cancers 
display both nuclear and cytoplasmic p-Akt(Ser473) (56). These 
observations may suggest a role of nuclear p-Akt in aggressive 
or invasive disease. This hypothesis is supported by findings that 
nuclear p-Akt is associated with migration in vitro (48), and that 
in the TRPV mouse model, p-Akt is both cytoplasmic and nuclear 
in primary tumors, but is predominantly nuclear in metastases 
(38). By contrast to these studies, Zafón et al. (60) did not find 
any difference in cytoplasmic or nuclear p-Akt(Ser473) staining 
between papillary thyroid cancers with or without associated 
lymph node metastases at the time of diagnosis, even though 
the group with associated metastases had a greater proportion 
overexpressing RET or EGFR.
MeDULLARY THYROiD CANCeR
p-Akt(Ser473) expression has also been investigated in medullary 
thyroid cancer, which unlike other subtypes of thyroid cancer is 
derived from parafollicular C-cells. Evidence from hereditary 
cancers and in  vitro work suggests that the PI3K/Akt pathway 
may play a role in medullary thyroid carcinogenesis (74). Only 
three studies have so far reported p-Akt staining in human 
medullary thyroid cancers, and these used tissue microarrays 
(Table 1). p-Akt(Ser473) expression was strongly associated with 
p-mTOR and p-p70S6K in a series of 49 cancers, suggesting that 
the Akt/mTOR pathway is active in these tumors, and is therefore 
potentially amenable to therapy (66), but there was no association 
between p-Akt expression and prognosis or clinicopathological 
factors (66). Furthermore, in a study of 23 cancers, p-Akt(Ser473) 
and mTOR staining were predominantly weak, with no associa-
tion between p-Akt(Ser473) and overall or disease-free survival 
(67). However, Tamburrino et al. (68) found significant correla-
tions between p-Akt(Ser473) and p-ERK staining and Pennelli 
et  al. (75) also remarked on the preferential activation of the 
PI3K/Akt pathway, detected as high levels of p-Akt(Ser473) on 
western blotting in medullary thyroid carcinoma cases which had 
mutant RAS.
In the Tamburrino study (68), a series of 53 human medullary 
thyroid carcinoma tissues (18 hereditary, 35 sporadic), riboso-
mal protein p-S6(Ser235/236) was frequently overexpressed 
compared to normal thyroid tissues. It should be noted that 
the normal thyroid used was largely C cell-free, and therefore 
the malignant cells were not being compared with their normal 
counterparts; however, other reports make no mention of positive 
C-cells in control normal thyroid tissue, which is classed as nega-
tive. Of the medullary tumors, 76% had detectable p-Akt(Ser473) 
and 96% expressed detectable levels of S6K. That S6K is more 
frequently detected than p-Akt is similar to findings of Pringle 
et al. (39) in their mouse model of follicular thyroid carcinoma. 
By contrast to p-Akt(Ser473), only 39% of tumors had detectable 
p-Akt(Thr308), perhaps due to difference in the sensitivity of the 
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antibodies, as suggested by the authors, although far fewer tumors 
were stained for p-Akt(Thr308) than p-Akt(Ser473). A further 
relevant Akt target in medullary thyroid carcinoma may be the 
tumor suppressor, Programed Cell Death 4 (PDCD4), which 
Akt inactivates, which showed reduced expression in medullary 
thyroid carcinoma (75). Overall, immunohistochemistry results 
support previous observations of elevated Akt/mTOR signaling in 
medullary thyroid carcinoma. Furthermore, rapamycin reduced 
tumor volume of RET mutant MZ-CRC-1 xenografts in NOD/
SCID mice (68).
PARATHYROiD CARCiNOMA
Parathyroid carcinomas are rare, accounting for <1% of pri-
mary hyperparathyroidism (76). These cancers are aggressive, 
with high risk of metastasis and recurrence. Parathyroid cancers 
remain poorly understood, and surgery remains the mainstay of 
treatment; little is known about the role of PI3K/Akt signaling in 
these tumors. p-Akt expression has been described in a cohort 
of 10 parathyroid carcinomas and 25 parathyroid adenomas 
(Table  2). In this study, p-Akt expression was reported to be 
variable; however, expression appeared to be lower in carcino-
mas: on average 28% of tumor cells were positive in carcinomas, 
with 87% positive in adenomas, although no statistical analysis 
was presented (77). p-mTOR and FoxO1 expression were also 
examined in this cohort, and the authors suggested that there 
was no marked alteration in their expression in parathyroid 
carcinoma compared to adenoma (77), but the exact picture 
remains unclear. The PI3K/Akt pathway has, to the best of 
our knowledge, remained otherwise unstudied in parathyroid 
neoplasia. However, mutation analysis from a single patient has 
identified an activating mutation in PIK3CA from the primary 
tumor, and RNA-seq datasets demonstrated overexpression of 
AKT2 mRNA in one of two areas of recurrence (78), perhaps 
suggesting that this pathway may be an important area for 
future research.
PiTUiTARY TUMORS
Pituitary adenomas are among the most common intracranial 
neoplasms. Approximately 60% of pituitary tumors are function-
ally active, of which prolactinomas [prolactin (PRL) secreting 
tumors] are the most common subtype. The remaining functional 
tumors are somatotroph adenomas [growth hormone (GH) secret-
ing], corticotroph adenomas [adrenocorticotrophic hormone 
(ACTH) secreting], thyrotroph adenomas [thyroid- stimulating 
hormone (TSH) secreting], and gonadotroph adenomas [follicle-
stimulating hormone (FSH) and luteinizing hormone (LH) 
secreting]. Non-functioning pituitary adenomas (NFPA) do not 
exhibit hypersecretion. Of note, some pituitary adenomas are 
endocrinologically “silent”: they produce hormones that are not 
secreted (99). Malignancy is rare, however, local invasion, recur-
rence, or treatment failure occur in a proportion of cases.
The PI3K/Akt pathway plays a role in maintaining viability 
of rat pituitary adenoma cell lines (GH3, LβT2) (100, 101), sug-
gesting a potential role for Akt in pituitary tumorigenesis. This 
is further supported by work in TRβPV/PV mice and MENX (mul-
tiple endocrine neoplasia-like syndrome) rats. TRβPV/PV mice 
possess a knock-in mutation of the TRβ gene and spontaneously 
develop TSH-secreting pituitary adenomas (TSHoma) with age 
(102); MENX rats harbor biallelic frameshift mutations of the 
CDKN1B gene (encoding p27KIP1) and develop pituitary adeno-
mas alongside multiple other endocrine tumors (103). Pituitary 
adenomas from TRβPV/PV mice show increased phosphorylation 
of Akt (Ser473), mTOR and S6 on western blotting, and PI3K/
Akt inhibition decreases pituitary tumor mass and increases 
apoptosis (102). Likewise, immunohistochemistry demon-
strated increased levels of p-Akt(Ser473) in pituitary adenomas 
from MENX rats, and increased p-Akt(Ser473), p-Akt(Thr308), 
and p-S6(Ser24/44) in primary cultures of tumor cells (104). 
The MENX rat model has been useful in demonstrating anti-
proliferative and pro-apoptotic function of the dual PI3K/mTOR 
inhibitor NVP-BEZ235 in vivo and in organotypic culture (105).
Compared with normal tissue, human pituitary adenomas 
showed an increased percentage of cells immunostaining 
for p-Akt(Ser473) on immunohistochemistry, and increased 
p-Akt:total Akt ratios on western blotting suggest that Akt 
phosphorylation is increased in these tumors (79). Likewise, in a 
study of three gonadotropinomas, levels of p-Akt(Thr308) were 
elevated in protein lysates of tumors versus normal pituitaries 
(101), but to our knowledge there have been no larger studies 
examining Akt phosphorylation at Thr308 in human pituitary 
tumors. Few studies have investigated the prognostic role of 
p-Akt in pituitary tumors. However, in partially resected NFPA, 
p-Akt(Ser473) immunostaining was associated with tumor 
recurrence, suggesting that Akt phosphorylation may be of 
use in risk stratification in these cases (81). A recent study has 
also revealed that endothelial expression of p-Akt(Ser473) in 
pituitary tumors is positively associated with tumor size, leading 
the authors to hypothesize that Akt activation may play a role in 
angiogenesis in these tumors (82). A study of ACTH-producing 
pituitary adenomas has revealed significant associations between 
the immunostaining for p-Akt(Ser473) and prohormone con-
vertase 2 (a serine protease involved in proteolytic cleavage of 
prohormones), but the relevance and implications of these find-
ings remain unclear (80).
The mechanism for Akt over-activation in pituitary tumors 
is likely to be multifactorial. PIK3CA amplifications or muta-
tions occur in around a third of pituitary tumors (106, 107), and 
PIK3CA mutations are associated with invasive disease (106). 
It is well established that there is altered or overexpression of 
growth factors and growth factor receptors in pituitary tumors, 
for example alterations in epidermal growth factor receptor 
(EGFR) and fibroblast growth factor receptor (FGFR) signal-
ing, which could also drive Akt activation [reviewed in Ref. 
(108)]. In particular, Eps8 (Epidermal Growth Factor Receptor 
Pathway Substrate 8), which signals downstream of these recep-
tors, promoted cell survival through modulation of Akt activity 
in Eps8-overexpressing LβT2 gonadotrope cells in  vitro, and 
immunoblotting demonstrated that both p-Akt(Thr308) and 
Eps8 are overexpressed in human pituitary adenomas (101). 
Hepatocyte growth factor receptor (HGFR/c-met) signaling 
TABLe 2 | Results of immunohistochemical staining studies for p-Akt(Ser473) in non-thyroid tumors of endocrine tissue origin.
Antibody Specimens Key results Author 
(reference)
Parathyroid carcinoma
p-Akt(Ser473) CST, 
736E11, 1:50
10 parathyroid carcinoma On average 87% of tumor cells were positive in adenomas, and 28% of tumor  
cells were positive in carcinomas
Erovic et al. 
(77)25 parathyroid adenoma (Canadian 
Specimens)
Tumours of the pituitary
p-Akt(Ser473) CST, 
Rabbit Polyclonal, 1:50
40 pituitary adenoma (ACTHoma 10, 
GHoma 10, PRLoma 10, NFPA 10)
Increased expression compared with normal pituitary. No correlation with  
p27 KIP1 expression
Musat et al. 
(79)
10 Normal pituitary
p-Akt (unspecified) 
SC, 1:100
19 ACTHoma (Japanese Specimens) Correlation between expression of p-Akt and PC2 Iino et al. 
(80)
p-Akt(Ser473) CST, 
D9E, 1:50
35 incompletely resected NFPA Expression associated with recurrence (sensitivity: 69.2%, specificity: 66.7%) Noh et al. 
(81) 
p-Akt(Ser473) CST, 
D9E 1:100
30 pituitary adenoma (GHoma 7, 
PRLoma 6, ACTHoma 4, FSHoma 1, 
NFPA 12) (Italian Specimens)
p-Akt correlated with c-met and HGF, but not PI3K. Endothelial p-Akt expression 
associated with tumor size
Trovato 
et al. (82)
Tumours of the adrenal cortex
p-Akt(Ser473) CST 4 adrenocortical carcinoma p-Akt detectable in normal adrenal cortex. Focal expression of p-Akt in  
adrenocortical carcinoma
Fassnacht 
et al. (83)2 normal adrenal (from renal cancer 
surgery) (German Specimens)
p-Akt(Ser473) ILT 24 adrenocortical carcinoma Adrenocortical carcinoma showed increased expression of p-Akt compared with 
adenomas or normal tissue, along with increased p-IGF1R
Barlaskar 
et al. (84)2 adrenocortical adenoma
4 normal
p-Akt (Ser473) CST 121 adrenocortical carcinoma p-Akt expression not detected in normal adrenal or adrenocortical adenoma, but 
detected in 33% of adrenocortical carcinoma. Low SGK1 with strong p-Akt associated 
with poor prognosis. No correlation between p-Akt and nuclear β-catenin staining
Ronchi 
et al. (85)15 adrenocortical adenoma
5 normal adrenal
p-Akt (Ser473) CST 
Rabbit mAb, D9E, 
1:25
47 adrenocortical carcinoma (Dutch 
Specimens)
p-Akt expression associated with better prognosis after mitotane monotherapy Hermsen 
et al. (86)
Tumours of the adrenal medulla – neuroblastoma
p-Akt(Ser473) CST 4 adrenocortical carcinoma p-Akt detectable in normal adrenal cortex. Focal expression of p-Akt in adrenocortical 
carcinoma
Fassnacht 
et al. (83)2 normal adrenal (from renal cancer 
surgery) (German Specimens)
p-Akt(Ser473) CST, 
1:400
24 neuroblastoma No significant difference between differentiated and undifferentiated tumors Qiao et al. 
(87)
p-Akt(Ser473) Rabbit 
mAb, 1;100, CST
116 neuroblastoma (German 
Specimens)
p-Akt(Ser473) and/or p-Akt(Thr308) expression in majority of tumors. High expression 
correlated with MYCN amplification or 1p36. Expression of p-Akt(Thr308) or 
expression of both isoforms associated with stage IV disease and worse prognosis
Opel et al. 
(88)
p-Atk(Thr308) Rabbit 
mAb, 1:100, CST
p-Akt(Ser473) CST 30 neuroblastoma Cytoplasmic p-Akt expression neuroblastoma. Negative staining in normal medulla Johnsen 
et al. (89)
p-Akt(Ser473) SC, 
polyclonal rabbit, 
1:100
55 mass screening neuroblastoma, 
21 paired metastasis (Japan, Canada)
Expression lower in neuroblastoma from mass screening, and lower in younger 
patients. Expression correlates with PARP-1 
Sartelet 
et al. (90)
55 matched unscreened 
neuroblastoma, 21 paired metastasis 
(France)
p-Akt(Ser473) SC, 
S473-r, 1:100
101 primary neuroblastoma, 39 
metastasis (French specimens)
Expression in majority of tumors, and expression correlation with PI3K, Akt, VEGFR1, 
VEGF, TRKB and IGF1R. Not associated with survival
Sartelet 
et al. (91)
p-Akt(Ser473) 
SC S473-r, rabbit 
polyclonal, 1:100
280 primary neuroblastoma, 97 
metastasis (French and Canadian 
specimens)
Expression in almost all tumors. Expression higher in CD133+ tumors Sartelet 
et al. (92)
Tumours of adrenal medulla – pheochromocytoma
p-Akt(Ser473) CST 8 phaeochromocytoma Increased expression compared to normal adrenal medulla Fassnacht 
et al. (83)2 normal adrenal (from renal cancer 
surgery) (German Specimens)
p-Akt(Ser473) CST, 
736E11, 1:50
39 primary and 8 metastatic 
pheochromocytoma
Trend for increased levels in primary tumors versus normal medulla, and in  
metastasis versus primary tumors
Chaux et al. 
(93)
19 normal adrenal medulla (American 
Specimens)
(Continued)
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Antibody Specimens Key results Author 
(reference)
Gastroenteropancreatic neuroendocrine tumours
p-Akt(Ser473) 
Abcam, ab89232, 
1:100
85 gastroenteropancreatic NET Cytoplasmic staining in more than 70% of tumors, vascular endothelium also positive. 
p-Akt expression correlated with p-EGFR and p-ERK1/2
Shah et al. 
(94)5 paraganglioma
4 NET of unknown origin
p-Akt(Ser473) CST, 
587F11, 1:100, Mouse 
mAb
46 gastroenteropancreatic NET 
(American Specimens)
Diffusely granular cytoplasmic staining in 61% of tumors. No correlation with grade, 
size or metastasis
Ghayouri 
et al. (95) 
p-Akt(Ser473) CST, 
736E11, 1:50 Rabbit 
mAb
20 gastroenteropancreatic NET 
(Japanese Specimens)
Cytoplasmic and nuclear p-Akt staining, co-expression with p-mTOR in some  
tumor cells
Shida et al. 
(96)
p-Akt(Ser473) CST 25 neuroendocrine carcinoma 
(carcinoid any site or pancreatic 
NET; treated with everolimus and 
octreotide)
p-Akt(Ser473) immunostaining of archival tumor blocks not associated  
progression-free survival. High p-Akt(Thr308) from pre-treatment FNA measured  
using RPPA associated with longer PFS
Meric-
Bernstam 
et al. (97)
p-Akt(Ser473) CST 195 NET (124 small intestinal, 14 
pancreatic, 52 others)
Correlations between members of the mTOR pathway. p-Akt expression correlated 
with expression of p-PDPK1 and p-mTOR, but was not associated with prognosis
Qian et al. 
(98)
CST, Cell Signaling Technology; SC, Santa Cruz Biotechnology Inc.; ILT, Invitrogen Life Technologies; mAb, monoclonal antibody; GHoma, somatotroph adenomas (growth hormone 
secreting); ACTHoma, corticotroph adenomas (adrenocorticotrophic hormone secreting); TSHoma, thyrotroph adenomas (thyroid-stimulating hormone secreting); FSHoma, 
follicle-stimulating hormone secreting; NFPA, Non-functioning pituitary adenomas; NET, neuroendocrine tumors; HGF, hepatocyte growth factor; SGK1, serum GC kinase 1; 
VEGFR1, vascular endothelial growth factor receptor-1; TRKB, neurotrophic tyrosine kinase receptor type B; p-IGF1R, phosphorylated insulin-like growth factor 1 receptor; p-EGFR, 
phosphorylated epidermal growth factor receptor; p-PDPK1, phosphorylated phosphoinositide-dependent kinase-1; FNA, fine needle aspirates; RPPA, Reverse Phase Protein Array; 
PFS, progression-free survival.
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may act as a further driver for Akt activation: immunohisto-
chemistry has demonstrated significant association between 
p-Akt(Ser473), c-met and HGF in human pituitary adenomas 
(82). The role for PTEN is less clear: while no PTEN mutations 
were identified in 33 pituitary tumors, and PTEN mRNA levels 
were comparable to normal tissue, nuclear PTEN expression 
was reduced in pituitary tumors (79). Investigations are needed 
to determine whether this results in activation of nuclear Akt 
pools. Interestingly, it has also been suggested that altered levels 
of microRNAs may play a role in pituitary tumorigenesis by 
modulating PI3K/Akt signaling via regulation of PTEN expres-
sion (109).
Downstream PI3K/Akt signaling in human pituitary tumors 
remains relatively poorly understood. Nuclear p27KIP1 is reduced 
in human pituitary adenomas, potentially consistent with cyto-
plasmic sequestration of p27KIP1 by Akt activity; however, the 
lack of correlation between p-Akt(Ser473) and p27KIP1 expression 
means conclusions must remain cautious (79). Pituitary adeno-
mas have also been reported to have increased levels of mTOR 
activation, as measured by phosphorylation of downstream S6, 
with GHomas showing the most marked elevation of mTOR 
activity (110). However, mTOR activity appeared to be independ-
ent of PI3K/Akt signaling in pituitary adenoma cells on primary 
culture, and mTOR activity was not related to clinicopathological 
characteristics in the sample of 53 pituitary adenomas (110). 
Increased Cyclin D1 expression has been consistently reported 
in non-functioning pituitary tumors (111, 112). This is partially 
due to Cyclin D1 (CCND1) gene amplification, which occurs 
in around 25% of pituitary adenomas (111). Overexpression of 
Cyclin D1 in tumors without gene amplification may suggest 
upstream pathways such as PI3K/Akt signaling (112). However, 
although reduced levels of double phosphorylated c-Myc (Thr62/
Ser58) are potentially consistent with activation of the PI3K/Akt 
pathway, phosphorylated and total TSC2 and mTOR levels were 
unchanged (112).
Targeting PI3K/Akt/mTOR signaling is of potential thera-
peutic interest in human pituitary tumors. mTOR inhibition 
reduces viability of human pituitary tumor cells in  vitro (113). 
Interestingly, in human NFPA cells, a response to everolimus was 
more likely in cells originating from younger patients, of female 
gender, with invasive macroadenomas (113). As in other cell types, 
mTOR inhibition induces Akt activation in pituitary cells in vitro, 
and this may contribute to resistance to mTOR inhibitors, which 
may limit their clinical efficacy (114). Therefore, concomitantly 
targeting the upstream PI3K/Akt pathway is potentially promis-
ing: combining rapamycin with octreotide (a somatostatin analog) 
more effectively suppresses pituitary tumor cell proliferation than 
rapamycin alone, with combination treatment proving effective in 
NFPA cells resistant to single agent rapamycin (114). Likewise, in 
primary cultures of pituitary tumor cells from MENX rats, cell 
viability is more effectively reduced by the dual PI3K/mTOR 
inhibitor NVP-BEZ235 than by everolimus alone (104). Targeting 
the PI3K/Akt/mTOR pathway could also be combined with more 
traditional treatment modalities in pituitary tumors, potentially 
increasing efficacy and/or reducing toxicity by allowing dose 
reduction: mTOR inhibitors increase radiosensitivity of pituitary 
tumor cells in vitro (115), and temozolomide and XL765 (a dual 
PI3K/mTOR inhibitor) synergistically inhibit cellular prolifera-
tion in vitro and reduce tumor growth and hormone secretion in 
xenograft mice (116). Despite the promising preclinical work, 
experience in human pituitary tumors is limited to an isolated 
report of unsuccessful treatment with everolimus in a single 
patient with a pituitary carcinoma (a rare entity defined by pres-
ence of metastasis), and as such, no clear conclusions can be made 
about efficacy of PI3K/Akt/mTOR inhibition in human pituitary 
tumors (117).
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ADReNAL CORTeX
Most adrenocortical tumors are sporadic, but adenomas or 
carcinomas may occur in association with familial cancer syn-
dromes (118). Adrenocortical carcinomas (ACC) are generally 
highly aggressive tumors, with an incidence of approximately 1–2 
cases per million per year (119). Complete surgical resection is 
potentially curative; however, recurrence is relatively common. 
Treatment of advanced disease remains challenging: mitotane 
plus etoposide, doxorubicin and cisplatin is the first-line cyto-
toxic therapy but response rate is relatively poor (119). The patho-
physiology of these rare tumors remains poorly understood, but 
a greater understanding of key signaling pathways may provide 
much-needed treatment options.
Evidence suggests that IGF signaling may be of great 
clinical interest in ACC. Patients with Beckwith–Wiedemann 
Syndrome, in whom deregulated imprinting at 11p15.5 leads to 
biallelic expression of IGF2, have a 5% incidence of ACC (118). 
Furthermore, IGF2 is the most overexpressed gene in a large 
proportion of sporadic ACC and on transcriptome analysis 
forms part of a cluster of eight overexpressed genes characterizing 
malignant ACC rather than prevalent adrenocortical adenomas 
(ACA) (120). Early clinical trials of IGF-1R inhibitors showed 
potentially promising results in these rare cancers (121, 122), but 
unfortunately, the IGF-1R and insulin receptor inhibitor linsitinib 
showed limited therapeutic benefit in a recent phase III trial (123). 
Nonetheless, the majority of these tumors possess overactivation 
of the IGF pathway and/or enhanced EGFR signaling (124, 125), 
which could serve as further driver of Akt activation. Altered 
β-catenin expression may also regulate Akt activation in these 
tumors: β-catenin expression is known to be altered in 20% of 
ACC, and knockdown of β-catenin in human ACC cells in vitro 
decreases Akt phosphorylation (126), although no correlation 
was seen between p-Akt(Ser473) and β-catenin immunostaining 
in human tumors (85).
Akt activation appears to be enhanced in a subset of human 
ACC in  vivo (Table  2). An early study by the Allolio group 
showed that total Akt and p-Akt(Ser473) were detectable in the 
adrenal cortex but not in the medulla, and ACC exhibited focal 
enhancement of p-Akt(Ser473), potentially suggesting local 
activation of Akt signaling in these cancers (83). The results 
from western blotting did not necessarily correlate with results 
obtained by immunohistochemistry, but this perhaps reflected the 
focal expression of p-Akt and also areas of stromal and necrotic 
tissue which are both negative for total Akt and p-Akt in ACC 
(83). A more recent study found elevation of both total Akt and 
p-Akt(Ser473) in six adrenocortical adenomas and four ACCs 
compared to normal adrenocortical controls on western blotting 
(127). Nakamura et al. (128) also detected p-Akt(Ser473) in the 
adrenal cortex in their immunohistochemical study, but compar-
ing ACC (41 samples) with ACA (54 samples) there was a similar 
percentage of p-Akt(Ser473) positive cells. By contrast, another 
group demonstrated increased p-Akt(Ser473) expression in 24 
ACC compared with 22 ACA or 4 normal tissue samples (84). 
Likewise, a more recent study of 121 ACC from the Allolio group 
describes enhanced p-Akt(Ser473) immunostaining in one-third 
of carcinomas, which was not seen in ACA or normal tissue (85).
The association between p-Akt(Ser473) expression and 
survival in ACC remains unclear. In one study, p-Akt(Ser473) 
expression alone was not associated with prognosis, but high 
p-Akt and low SGK1 (Serum/Glucocorticoid Regulated Kinase 1) 
expression identified a subgroup with extremely poor prognosis 
(85). In contrast, in tissue microarrays of 45 ACC patients who 
received mitotane monotherapy, in which p-Akt was detected 
in 31% of tumors, Hermsen et  al. (86) unexpectedly found an 
association between p-Akt expression and longer overall survival, 
although there was no association with objective response to 
mitotane.
Early results suggest that targeting p-Akt signaling may be a 
promising therapeutic strategy in ACC. mTOR inhibitors siroli-
mus and temsirolimus inhibit ACC cell proliferation in vitro (129). 
Likewise, everolimus treatment results in antitumor effects in 
primary adrenocortical cultures, ACC cell lines, and in xenograft 
mice (130). Of note, significant synergism is seen when everoli-
mus is combined with sorafenib (a tyrosine kinase inhibitor), 
suggesting that targeting signaling pathways at multiple levels 
may be of value in these tumors (130). Moreover, the dual PI3K/
mTOR inhibitor, NVP-BEZ235 inhibits Akt phosphorylation, 
reduces ACC cell proliferation in  vitro, and reduces tumor 
size in xenograft mice (131). The H295 cell line overproduces 
IGF2, which likely stimulates IGF-1R in an autocrine signaling 
loop, and this provided a useful model of the common IGF2 
overproduction in ACC; IGF2-neutralizing antibody increased 
the anti-proliferative effects of sirolimus (129). Encouragingly, 
the combination of an IGF-1R inhibitor and mTOR inhibition 
with cixutumumab (monoclonal antibody targeting IGF-1R) and 
temsirolimus resulted in 42% of patients with ACC achieving 
stable disease of at least 6 months (132).
ADReNAL MeDULLA: 
PHAeOCHROMOCYTOMA AND 
PARAGANGLiOMA
Phaeochromocytomas and paragangliomas are catecholamine-
secreting neuroendocrine tumors of chromaffin cells, either of 
the adrenal medulla (phaeochromocytoma) or extra-adrenal 
sympathetic or parasympathetic paraganglia (paraganglioma). 
Most phaeochromocytomas are apparently sporadic, although 
a significant proportion is associated with genetic syndromes, 
such as MEN2A, Neurofibromatosis (NF1), Von-Hippel Lindau 
(VHL), or germline mutations in SDHx (133). In the vast majority 
of cases, the disease is benign and surgical excision is curative. 
While estimates vary, approximately 10% are malignant, and in 
these cases current treatment options remain limited (134, 135).
In  vitro evidence suggests that the PI3K/Akt pathway is of 
interest in phaeochromocytoma. It is well established that Akt 
signaling promotes survival of rat PC12 pheochromocytoma 
cells and neuronal cells in  vitro, protecting against apoptosis 
induced by a range of stimuli, including cytotoxic chemotherapy 
(136–139). Furthermore, PI3K/Akt signaling may promote 
the neuroendocrine phenotype as inhibition of PI3K/Akt in 
PC12 cells reduces neuroendocrine marker expression and 
hormone secretion (139). PI3K/Akt signaling is also essential for 
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anchorage-independent growth in rat fibroblasts expressing RET-
MEN2A (71); RET-MEN2A germline mutations are responsible 
for MEN2A, which leads to pheochromocytoma in approximately 
50% of patients – therefore these results suggest that this pathway 
may be critical in tumorigenesis in these patients.
Mice haplodeficient for PTEN develop bilateral tumors of the 
adrenal medulla with high penetrance; concomitant deletion of 
AKT1 (PTEN+/−AKT1−/−) in these rodents significantly reduces 
the size of the adrenal medulla and the tumors, and reduces the 
occurrence of high grade lesions, suggesting that Akt signal-
ing plays a role at least in advanced tumors in these mice (34). 
However, PTEN mutation does not appear to be a major driver for 
Akt activation in human phaeochromocytomas, as PTEN muta-
tions are reported to be rare in human tumors (83). A second 
rodent model, produced by ectopic overexpression of ErbB-2 in 
mice, leads to catecholamine-producing adrenal tumors with 
greatly reduced PTEN protein levels, and increased Akt phos-
phorylation and cyclin D1 (140). In this mouse model, while 
PTEN mRNA levels were somewhat reduced, this reduction did 
not appear to account for the marked reduction in protein levels, 
leading the authors to suggest that post-translational regulation 
of PTEN may play an important role (140). MENX rats represent 
a third rodent model of pheochromocytoma; these rats possess 
homozygous frameshift mutations in CDKN1B and develop 
tumors of the adrenal medulla alongside other endocrine tumors 
(141). Adrenal tumors of MENX rats overexpress the secretin 
receptor, and PI3K/Akt signaling acts downstream to promote 
cell proliferation (141). However, this pathway does not appear to 
be directly applicable to humans, as human phaeochromocytoma 
rarely overexpress the secretin receptor (141). MENX pheochro-
mocytomas also overexpress secreted BMP7 (Bone Morphogenic 
Protein 7); this parallels elevated immunoreactivity for BMP7 in 
human pheochromocytoma samples, detected in 72% of 184 
tumor samples on tissue microarray (150 pheochromocytomas 
and 34 paragangliomas) (142), and BMP7 knockdown was 
demonstrated to promote proliferation, migration, and invasion 
primary cultures of MENX-derived pheochromocytomas. From 
in vitro models, including PC12 cells transfected to overexpress 
BMP7, evidence was provided for non-canoncial signaling 
through the PI3K/Akt/mTOR pathway leading to overexpres-
sion of integrin β1, responsible for the BMP7-induced cancer 
phenotypes (142).
Two separate studies have shown elevated levels of 
p-Akt(Ser473) in human phaeochromocytoma using western 
blotting (83, 139). In one study, expression of p-Akt(Ser473) was 
further categorized in a smaller sample of human phaeochromo-
cytoma using immunohistochemistry, demonstrating minimal or 
absent immunostaining in normal tissue, with increased expres-
sion in tumors (83). A larger sample of 39 primary and 8 unrelated 
metastatic pheochromocytoma has shown similar results, with 
higher levels of p-Akt(Ser473) in primary tumors than normal 
tissue, and higher levels in metastatic than primary tumors, but 
these differences were not statistically significant (93). Reports 
of PTEN immunostaining are less consistent, with reports of 
both increased (83) and decreased (93) levels in these tumors. 
Further evidence of altered PI3K/Akt/mTOR signaling is sug-
gested by increased expression of S6K1 and reduced expression 
of p27KIP1 in human pheochromocytoma compared with normal 
tissue and elevated pS6 in metastatic tumors (93). Evidence also 
suggests that mTOR signaling may be driven by loss-of-function 
TMEM127 (transmembrane protein 127) mutations in some 
cases: germline TMEM127 mutations have been identified in a 
proportion of familial phaeochromocytomas, and in around 2% 
of apparently sporadic disease, with loss of heterozygosity in 
tumor specimens (143, 144). Functional TMEM127 appears to 
be act as a negative regulator of mTOR, with no apparent effects 
on Akt activation, therefore TMEM127 mutation may provide an 
alternative Akt-independent pathway for mTOR overactivation 
in these tumors (143).
Despite the apparent importance of PI3K/Akt/mTOR signal-
ing in phaeochromocytoma, there has been limited experience 
and success in targeting this pathway clinically. Use of everolimus 
inhibitors in four patients with malignant pheochromocytoma 
showed disappointing results (135). However, dual inhibitors 
of mTORC1 and mTORC2 show promise in preclinical work. 
Dual mTORC1/2 inhibitors, unlike rapamycin, are able to sig-
nificantly decrease Akt Ser473 phosphorylation. mTOR inhibitor 
AZD8055 significantly reduced the tumor and metastatic burden 
in athymic nude mice injected with cells of the metastatic mouse 
pheochromocytoma-derived cell line, MTT, and decreased 
survival of primary human pheochromocytoma cells in culture 
(145). Compared to rapamycin, dual mTORC1/2 inhibitor PP242 
more effectively increased apoptosis of rat PC12 phaeochromo-
cytoma xenografts, with a more marked increase in levels of 
pro-apoptotic Bax and reduction in levels of anti-apoptotic Bcl-
2, leading to smaller tumors than control mice or those treated 
with rapamycin (124). Furthermore, dual mTORC1/2 inhibition 
more effectively suppressed VEGF (vascular endothelial growth 
factor) and angiogenesis (124). Knockdown of VEGFR-2 in PC12 
cells reduced the ability of tyrosine kinase inhibitor sunitinib 
(which has strong affinity for VEGFRs) to inhibit Akt and mTOR 
phosphorylation and attenuated sunitinib-induced apoptosis 
(146). Together these observations suggest a positive feedback 
loop involving VEGF signaling through VEGF-R2 and PI3K/
Akt/mTOR pathway activation. Inhibition of multiple hallmarks 
of cancer by dual mTORC1/2 inhibitors provides rationale for 
potential use in human pheochromocytoma.
ADReNAL MeDULLA: NeUROBLASTOMA
Neuroblastoma is derived from the neural crest and is the most 
common extracranial cancer of childhood, accounting for 
approximately 13% of pediatric cancer deaths (147). These tumors 
most commonly occur in the adrenal medulla, but may occur 
at any site of the sympathetic nervous system. Neuroblastomas 
show marked heterogeneity in their clinical course: while some 
spontaneously regress, others are widely metastatic, resistant to 
chemotherapy, and carry a high mortality. MYCN amplification 
occurs in 25% of primary tumors, and is an important marker 
of poor prognosis (148). Mass screening for neuroblastoma once 
appeared promising, however, such programs are now believed to 
result in overdiagnosis and overtreatment of biologically favorable 
tumors, at least a proportion of which would have spontaneously 
regressed or matured (148, 149).
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In recent years, there has been increasing focus on the 
PI3K/Akt signaling pathway in neuroblastoma. In  vitro work 
demonstrates that PI3K/Akt promotes neuroblastoma cell sur-
vival, protecting cells from various apoptotic stimuli including 
cytotoxic chemotherapy (88, 91, 150–152). Akt2 activity may 
also promote metastatic potential, as silencing Akt2 reduces 
anchorage-independent growth, migration, and invasion of neu-
roblastoma cells in vitro, and decreases their metastatic poten-
tial in mice (153). Furthermore, in vitro evidence suggests that 
Akt signaling interacts with key pathways in neuroblastoma. In 
neuroblastoma cells, Akt activation indirectly stabilizes N-Myc 
via negative regulation of GSK3β (154). Furthermore, N-Myc 
has been reported to regulate a microRNA, miR-184, that in 
turn targets the 3′UTR of AKT2 mRNA (155), suggesting that 
N-myc and PI3K/Akt signaling may form a positive feedback 
loop. Evidence also suggests that PI3K/Akt is activated down-
stream of Gastrin-Releasing Peptide (GRP)/Gastrin-Releasing 
Peptide Receptor (GRPR) and Brain-derived neurotrophic 
factor (BDNF)/TrkB signaling, which are reported to be over-
expressed in human neuroblastoma (151, 153, 156).
A number of studies have used immunohistochemistry 
to assess Akt activation in human neuroblastoma (Table  2). 
p-Akt(Ser473) immunostaining is reported to be increased in 
neuroblastoma compared with normal adrenal medulla (89), and 
studies have consistently reported detection of p-Akt(Ser473) in 
a large proportion of tumors (88, 89, 91, 157). p-Akt(Thr308) is 
less well investigated; however, its expression has been reported 
in at least 60% of human neuroblastoma (88). Interestingly, 
p-Akt(Ser473) has been reported to be more strongly expressed 
in less differentiated cells (157). However, a separate study has 
reported that while PTEN was lower in undifferentiated neuro-
blastoma, p-Akt(Ser473) levels were comparable in differentiated 
and undifferentiated tumors (156).
Activation of the PI3K/Akt pathways is suggested by find-
ings that p-Akt(Ser473) is correlated with downstream media-
tors, such as p-mTOR and cyclin-D1 (157) as well as potential 
upstream activators of the PI3K/Akt pathway, such as VEGFR 
and IGF-1R (91). Interestingly, p-Akt expression has also been 
reported to be higher in neuroblastoma expressing CD133 (91). 
CD133 has been identified as a cancer stem cell marker in other 
tumors and its expression is associated with worse prognosis in 
neuroblastoma (91, 158). The association between p-Akt and 
CD133 in human neuroblastoma is potentially important: CD133 
appears to promote a stem-cell like phenotype and chemoresist-
ance in vitro, and both these actions are at least partially mediated 
by the PI3K/Akt pathway (91, 158).
In a study of 116 neuroblastoma, p-Akt(Ser473) and 
p-Akt(Thr308) expression correlated with markers of poor 
prognosis, such as MYCN amplification, changes in 1p36, and 
stage IV disease. Furthermore, p-Akt(Ser473) and p-Akt(Thr308) 
expression were associated with worse event-free and overall 
survival in this sample (88). Notably, p-Akt(Ser473) immu-
nostaining showed fewer associations with prognostic markers 
and showed a weaker association with survival than immu-
nostaining for p-Akt(Thr308) or for both markers (88). While 
a second large study failed to show any association between 
p-Akt(Ser473) immunostaining and prognosis (91), expression 
of genes downstream of PI3K/Akt signaling has been associated 
with shorter overall survival (159). In addition, expression of 
p-Akt(Ser473) is significantly lower in tumors identified by mass 
screening than in other neuroblastomas (90). As discussed above, 
tumors identified by mass screening are rarely aggressive, have 
a substantially better prognosis, and may have otherwise have 
spontaneously regressed or matured (148, 149); it is possible that 
lower levels of Akt signaling could contribute to the favorable 
behavior of these tumors.
GASTROeNTeROPANCReATiC 
NeUROeNDOCRiNe TUMORS
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) 
are a heterogeneous group of neoplasms. GEP-NETs are 
derived from neuroendocrine cells of the gastrointestinal 
tract and pancreatic islets, with intestinal NETs accounting for 
approximately 50% of cases, and pancreatic NETs accounting 
for approximately 30% (160). GEP-NETs are rare, but their inci-
dence appears to be increasing (161). Most cases are sporadic; 
however, GEP-NET may occur in association with familial 
cancer syndromes such as MEN1, VHL, NF-1, and tuberous 
sclerosis. These tumors classically have an indolent course, 
but presentation often occurs at a late stage with metastases 
present at diagnosis (162). GEP-NETs can be divided into 
non-functional and functional tumors, with functional tumors 
resulting in clinical syndromes due to excessive hormone 
secretion. Small-intestinal NETs (carcinoids) present with 
carcinoid syndrome in 30% as a result of secretion of bioactive 
amines, resulting in an array of symptoms including vomiting 
and diarrhea (160). Approximately 50% of pancreatic neuroen-
docrine tumors (P-NET) are functional, producing gastrin 
(gastrinoma), insulin (insulinoma), glucagon (glucagonoma), 
or vasoactive intestinal peptide (VIPoma), or more rarely, other 
peptides/hormones (160). Surgery may cure localized GEP-
NET disease, however, systemic therapies are currently limited 
due to the poor response to traditional cytotoxic chemotherapy. 
In recent years, there has been increasing interest in targeting 
PI3K/Akt in these cancers.
Work in GEP-NET cell lines demonstrates that the PI3K/Akt 
pathway is a promising target for therapy. Several studies have 
demonstrated that inhibiting this pathway in  vitro (through 
PI3K inhibition, p-Akt inhibition, or siRNA) impairs cell pro-
liferation and in some cases survival (163–166). Notably, the 
effects of Akt inhibition appear to be isoform specific: in human 
P-NET (BON1) cells, cell viability is impaired by knockdown 
of Akt1 or Akt3, but promoted by knockdown of Akt2 (165). 
Furthermore, inhibiting the PI3K/Akt pathway has been shown 
to reduce the expression of neuroendocrine tumor markers, 
such as ASCL1 and CgA in pancreatic BON1 cells (166) – this 
is potentially clinically relevant, as targeting the PI3K/Akt path-
way may not only limit tumor cell proliferation or survival, but 
could conceivably control the troublesome symptoms resulting 
from hormone oversecretion (166). Evidence also suggests that 
the PI3K/Akt pathway may promote metastasis and invasion in 
these tumor cells: knockdown of Akt1, Akt2, or Akt3 impairs 
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neuroendocrine cell invasion (165), and knockdown of PTEN 
promotes liver metastasis in mouse xenograft models (167).
Gene expression profiling of P-NET has demonstrated that 
PTEN and TSC2 are downregulated in 50 and 35% of patients, 
respectively, and downregulation is predictive of poor survival 
(168). Loss of heterozygosity at the PTEN locus is common in 
P-NET, occurring in 53% of malignant tumors (169). However, 
PTEN mutations are relatively uncommon in these tumors: in 
an analysis of 68 P-NETs, 7% were found to have mutations in 
PTEN (8% had mutations in TSC2, and 1.4% had mutations 
in PIK3CA) (170). The PI3K/Akt pathway is perhaps less well 
studied in intestinal NET than P-NET, however, in a cohort of 48 
well-differentiated small intestinal NET (SI-NET), approximately 
one-third were found to have genetic alterations in the PI3K/Akt/
mTOR pathway, with amplification of Akt1/2 being the most 
common anomaly in this pathway (171).
Immunohistochemistry is also suggestive of dysregulation of 
the PI3K/Akt pathway in these cancers. PTEN expression has 
been reported to be either reduced (168) or show altered subcel-
lular localization (169) in P-NET. Lack of detection of PTEN and 
Akt2 positivity were both associated with failure to respond to 
systemic therapy in a mixed group of GEP-NETs, but despite this, 
Akt2 positivity was associated with longer overall survival (172). 
Low PTEN was associated with shorter time to progression and 
disease-free survival in a sample of 137 P-NET (168), and low 
PTEN expression was independently associated with shorter 
overall survival and metastasis-free survival in a sample of 160 
low and intermediate grade P-NET (173).
Assessment of p-Akt expression in GEP-NET suggests that 
the PI3K/Akt pathway is active in these tumors (Table 2). In a 
sample of 46 GEP-NET, immunohistochemistry demonstrated 
that 61% of tumors were positive for p-Akt(Ser473) (95), and in 
a mixed sample of NET from various sites, 76% showed positive 
immunostaining (94). Furthermore, in mixed samples of NET, 
there was significant association between p-Akt(Ser473) and 
p-EGFR (94) and between mTOR, PIK3CA, or p-EIF4EBP1 
and elevated Ki67 (98). Restriction of the analysis to intestinal 
NET revealed an association of these proteins with disease-
free survival (98). Likewise, western blotting suggests that 
p-Akt(Ser473) correlates with cyclin D1 expression in P-NET 
(174), suggesting that these signaling pathways are actively 
promoting cell proliferation in these cancers, although cyclin D1 
did not relate to tumor aggressiveness. Immunohistochemical 
studies have not demonstrated any significant association 
between p-Akt(Ser473) immunostaining and prognosis, tumor 
grade or other clinicopathological variables (94, 95, 97, 98), 
although this could perhaps reflect high levels of heterogeneity 
in samples examined. In a small sample of 14 gastrointestinal 
NET, high p-Akt levels measured by western blotting and a 
high p-Akt:PTEN ratio showed a non-significant association 
with shorter overall survival (163). The same study also reports 
a significant association between p-Akt expression and high 
levels of serum chromogranin A (CgA) expression (a serum 
marker of NET), and non-significant associations with the 
presence of carcinoid syndrome (163). While p-Akt(Ser473) has 
not convincingly been shown to be associated with prognosis, 
expression of its downstream target mTOR has been associated 
with tumor grade or worse prognosis (98, 175), but this has not 
been found in all studies (176).
There is increasing interest in targeting the PI3K/Akt/mTOR 
pathway, particularly in P-NET, which has been reviewed by 
Wolin (177). mTOR inhibitors have been investigated most exten-
sively and have shown promise: a phase III trial of everolimus in 
advanced, low-, or intermediate-grade P-NET showed prolonged 
progression-free survival versus placebo (11  months versus 
4.6  months) (178). Everolimus has now received Federal Drug 
Administration (FDA) approval for the treatment of advanced 
progressive P-NET. Markers of PI3K/Akt activation may be of use 
as biomarkers for sensitivity to mTOR inhibition in these tumors: 
cell lines with mutations in PIK3CA or PTEN are significantly 
more likely to be sensitive to rapamycin in vitro, and cells sensi-
tive to rapamycin show higher baseline levels of p-Akt(Ser473) 
and p-Akt(Thr308), and greater increases in p-Akt(Ser473) and 
p-Akt(Thr308) following rapamycin treatment (97). Furthermore, 
in patients with NET treated on a phase II trial of everolimus 
and octreotide, pre-treatment and on-treatment p-Akt(Thr308) 
levels measured by RPPA from fine needle aspirates (FNA) were 
associated with longer progression-free survival, and increases in 
Akt phosphorylation from paired samples was associated with 
response to treatment (97). Interestingly, however there was no 
association between immunostaining for p-Akt(Ser473) from 
archival tumor blocks and prognosis (97). There are limited data 
from clinical research relating to novel inhibitors of the PI3K/
Akt/mTOR pathway, although preclinical studies suggest that 
they may be of interest (177). A phase I trial of an allosteric oral 
Akt inhibitor, MK-2206, showed that treatment was safe with 
an acceptable side effect profile, furthermore, p-Akt(Ser473) 
immunostaining was reduced in post-treatment tumor biopsies 
compared with pre-treatment biopsies, and partial responses 
were noted in two patients with P-NET (179).
DiSCUSSiON
Overall, a significant weight of evidence suggests that the PI3K/
Akt pathway may have critical roles in multiple tumors of 
endocrine tissues. It is well established that Akt activation is a 
key mediator of cell proliferation, survival and motility, and, as 
discussed above, a significant body of in vitro work demonstrates 
that this is also applicable to endocrine cell lines. Furthermore, 
evidence from animal models, human cancer syndromes and 
immunohistochemical staining patterns in human endocrine 
tumors suggest that PI3K/Akt signaling may contribute to tumor 
progression, and, may even play a role in tumor initiation in some 
situations. The central role of the PI3K/Akt pathway in regulating 
many of the hallmarks of cancers makes it attractive as a potential 
indicator of prognosis, and a potential biomarker for response 
to therapies – especially in relation to novel agents targeting the 
PI3K/Akt pathway or downstream targets.
While immunohistochemical studies have undoubtedly 
provided invaluable insights into PI3K/Akt signaling in 
human cancers, concerns have been raised about the validity 
of p-Akt immunohistochemistry for assessment of Akt signal-
ing because phospho-proteins are relatively unstable in tissue 
samples, with a reported half-life of 20 min (180). Since many 
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studies rely on archival paraffin embedded material and the 
tumor collection process is not overseen by the researchers, 
the level of p-Akt activity in  vivo could be underestimated. 
Sajjad et al. (110) caution against using cadaveric material for 
this reason, favoring histologically normal tissue adjacent to 
tumors as control samples. Furthermore, negative feedback 
regulation of the PI3K/Akt pathway may lead to strong mTOR 
staining accompanied by relatively modest p-Akt staining (61). 
While individual downstream targets are useful as a readout 
for p-Akt activity in vitro where the PI3K–Akt is modulated 
by specific treatments, use of downstream targets to validate 
the activation of the PI3K–Akt pathway in vivo requires a set 
of diverse targets, since each target is subject to additional 
regulation. For example, ERK, S6K, GSK3β, and AMP-
activated protein kinase can all promote mTORC1 activity by 
phosphorylating TSC2 (1). It will also be valuable to identify 
which downstream targets are of relevance to specific cancers 
and tumor characteristics.
The vast majority of immunohistochemical studies of 
endocrine cancers have utilized p-Akt(Ser473) as a marker 
for Akt activation, with Cell Signaling Technology antibod-
ies being favored. Unfortunately, relatively few papers report 
which specific p-Akt(Ser473) antibody is used. Currently two 
of four rabbit monoclonal antibodies (D9E and 736E11) are 
recommended by the company for immunohistochemistry; 
there is also a rabbit polyclonal, which has commonly been 
used for immunohistochemistry. In addition, while it is clear 
that Akt activation in tumors can be revealed by enhanced 
p-Akt(Ser473) immunohistochemical staining and outcomes 
have been supported by western blotting results, exploration of 
the relative usefulness of p-Akt(Ser473) versus p-Akt(Thr308) as 
an indicator of Akt activation may be informative. Interestingly, 
when protein lysates from individuals with PIK3CA or AKT1 
mutations were compared with controls by western blotting 
using p-Akt(Ser473) and p-Akt(Thr308) antibodies, affected 
individuals showed significantly higher p-Akt(Thr308), but not 
p-Akt(Ser473) (29). In a study of non-small cell lung cancer, 
it was found that p-Akt(Thr308), but not p-Akt(Ser43) cor-
related with phosphorylation of three downstream substrates 
(PRAS40, TSC2, and TBC1D4), leading the authors to suggest 
that p-Akt(Thr308) represents a better measure of Akt activity 
in these tumors (181). However, an immunohistochemical 
study of colorectal carcinomas found that p-Akt(Ser473) 
staining correlated with phosphorylation of its downstream 
substrates GSK-3β and Bad, while p-Akt(Thr308) expression 
only correlated with phosphorylation of GSK-3β, and not that 
of Bad (182), perhaps suggesting substrate specific targeting. 
While in Figure 1, we depict activity of Akt in the absence of 
serine 473 phosphorylation toward TSC2 and GSK3β targets, 
Bhaskar and Hay (17) suggested that this may be conformation 
dependent, and put forward a suggestion that p-Akt(Thr308) 
may only be active in the membrane-bound form. No study 
has directly compared p-Akt(Ser473) and p-Akt(Thr308) 
in cancers of endocrine tissues. The Cancer Genome Atlas 
Research Network (30) compiled an RPPA data set including 
p-Akt(Thr308) and p-Akt(Ser473) to show that Akt is activated 
in RAS-like papillary thyroid tumors, however from these data, 
depicted as a heat map, it can be seen that Akt is not always 
highly phosphorylated on both sites.
Akt is subject to multiple additional post-translational modi-
fications including phosphorylation at other residues, ubiquit-
ination (lysine 63 linked), sumoylation, and glycosylation in the 
form of β-d-N-acetylglucosamine monosaccharide attachment; 
Akt2 can additionally be oxidated leading to intramolecular 
disulfide bonds between cysteine residues (183). These may 
regulate stability, trafficking, subcellular localization or substrate 
specificity of Akt. Sumoylation at Lys(276) is essential for Akt 
activation, which phosphorylates and promotes the activity 
of the sumoylation machinery, providing a positive feedback 
loop, which may be damped down by the sumoylation of PTEN 
(184). Glycosylation may occur at several sites, and Thr(305) 
and Thr(312) glycosylation may inhibit phosphorylation of Akt 
on Thr(308) (183). In murine pancreatic β-cells, glucosamine 
treatment led to decreased p-Akt(Ser473) in favor of O-linked 
N-acetylglucosamine at the same residue (185). Therefore, the 
complexities of regulation of Akt function by post-translational 
modification mean that we should be cautious in interpreting 
p-Akt(Ser473) as being fully active Akt.
Combination of PI3K inhibitors and mTOR inhibitors, dual 
mTORC1/2 inhibition, and mTOR and receptor tyrosine kinase 
inhibitors are strategies being explored for cancers of endocrine 
tissues in which the PI3K/Akt/mTOR pathway is hyperacti-
vated (21). In thyroid carcinomas, inhibition of PI3K or mTOR 
enhances iodine uptake, raising the possibility of enhanced 
sensitivity to 131I therapy in cancers in which this pathway is 
activated (186). In addition, two types of Akt inhibitors are 
in clinical development, catalytic ATP-competitive inhibitors 
that target active Akt, preventing access of phosphatases, and 
allosteric inhibitors that prevent recruitment to the cell mem-
brane and hence prevent activation. Using such inhibitors, 
the first type would lead to elevated levels of phosphorylated 
Akt, while the second type would prevent phosphorylation. 
Difficulties arise with activation of feedback pathways and 
compensatory pathways subsequent to Akt inhibition. Such 
issues, along with off target effects, need to be considered 
to ascertain dosing schedules that are sufficient to give long 
term inhibition. Further, it will be important to ascertain 
what level of active Akt would be required in a particular 
tumor before targeting of the PI3K/Akt pathway is likely to 
be of benefit (187).
Rather than selecting patients for treatment at random, better 
outcomes may result from a personalized approach to therapy 
by utilizing predictive biomarker screening strategies. To address 
this, Yan et al. (188) determined a set of biomarkers that can be 
used to predict patients likely to benefit from targeted Akt inhibi-
tion using GDC-0068, an inhibitor of the ATP competitive type. 
Of 100 protein and phospho-specific antibodies used in RPPA of 
lysates from tumor cell lines (PC3, prostate; U87, glioblastoma; 
MCF7.1, breast), p-Akt(Ser473) and p-Akt(Thr308) were elevated 
after treatment as expected, whereas substrates downstream of 
Akt, PRAS40, GSK-3β, mTOR, eIF4G, ATP citrate lyase, FoxO3A 
and S6, showed decreased phosphorylation. However, the array 
also revealed feedback activation of the MAPK pathway, with 
elevated p-ERK, and enhanced levels of HER3. Similar biomarker 
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responses were obtained in mouse xenograft models and in 
human tumor material from a “first in human” trial of GDC-0068 
in patients with advanced solid tumors. Interestingly, the tissue 
was removed by core needle biopsy and stroma and tumor cells 
were laser captured separately for RPPA analysis and validated by 
immunohistochemistry for p-Akt(Ser473), p-Akt(Thr308) and 
p-PRAS40(Thr246). While p-Akt(Ser473) and p-Akt(Thr308) 
were elevated in both tumor and stroma, p-PRAS40(Thr246) was 
only reduced in the tumor tissue, illustrating the importance of 
investigating the tumor cell population specifically. The authors 
propose that use of a biomarker set gives more robust readout for 
Akt inhibition than use of a single biomarker. Moreover, FNA 
or core needle biopsies allow comparison of pre-treatment and 
on-treatment functional proteomics by quantitative RPPA for 
components of the PI3K/Akt/mTOR pathway, particularly if tis-
sue collection is optimized to maintain antigenicity of phospho-
rylated proteins such as p-Akt by fixation in cold formalin within 
minutes of removal from the patient, which is more successful 
for small core biopsies than larger tissue specimens (189, 190). 
Sampling replicates can be used to account for tumor heterogene-
ity, but microdissection may be needed for tumors with stromal 
or other tissue elements. With careful consideration of these 
limitations, these methods may be developed further to allow 
prediction of drug response.
A full understanding of how Akt and its targets are regulated 
is important for the development of effective targeted therapies, 
rational development of therapeutic combinations, and a better 
identification of biomarker panels in tumors of endocrine tissues. 
Future work will need to explore the efficacy of further treatment 
combinations, such as combinations with XIAP or ERK inhibi-
tion, and it will be important to explore how best to promote 
apoptotic responses over cytostatic effects of treatment without 
engendering intolerable toxicity. Alongside these developments, 
biomarkers of the PI3K/Akt pathway have the potential to pre-
dict and monitor tumor response. Overall, current knowledge 
suggests that this pathway plays a substantial role in tumors in 
endocrine tissues, and hence lends strong justification for further 
work in this area.
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